Alnylam Pharmaceuticals Inc (ALNY)vsDefinium Therapeutics, Inc. (DFTX)
ALNY
Alnylam Pharmaceuticals Inc
$284.84
-3.46%
HEALTHCARE · Cap: $39.39B
DFTX
Definium Therapeutics, Inc.
$21.40
-2.95%
HEALTHCARE · Cap: $2.40B
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
DFTX
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.6%
Fair Value
$2410.60
Current Price
$284.84
$2125.76 discount
Intrinsic value data unavailable for DFTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 90 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
No standout strengths identified
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 35.3x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : DFTX
DFTX has a balanced fundamental profile.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 74.1x leaves little room for execution misses.
Bear Case : DFTX
The primary concerns for DFTX are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
ALNY profiles as a growth stock while DFTX is a value play — different risk/reward profiles.
DFTX carries more volatility with a beta of 2.38 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 23/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Definium Therapeutics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company is headquartered in New York, New York.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?